FINWIRES · TerminalLIVE
FINWIRES

Cytokinetics' Aficamten Gets UK Marketing Authorisation for Obstructive Hypertrophic Cardiomyopathy

By

Cytokinetics (CYTK) said Thursday that the United Kingdom's Medicines and Healthcare products Regulatory Agency has granted aficamten marketing authorisation across the UK for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Guidance from the National Institute for Health and Care Excellence states that aficamten can be used to treat symptomatic obstructive hypertrophic cardiomyopathy in eligible adults with NYHA class II to III, in England and Wales, the company said.

Aficamten can only be used as an add-on to individually optimised standard care including beta-blockers, non-dihydropyridine calcium-channel blockers or disopyramide, or alone if these treatments are contraindicated, Cytokinetics said.

The company said that the MHRA's assessment was based on data from its phase 3 SEQUOIA-HCM study in 282 adults.

Shares of the company were up 2.2% in Thursday trading.

Price: $80.30, Change: $+1.91, Percent Change: +2.44%

Related Articles

Wire

Houlihan Lokey Fiscal Q1 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Houlihan Lokey (HLI) reported fiscal Q1 adjusted earnings late Wednesday of $1.35 per diluted share, down from $2.14 a year earlier.Analysts polled by FactSet expected $1.64.Revenue in the three months ended June 30 fell to $511 million from $605 million a year earlier.Analysts expected $602.4 million.Houlihan Lokey shares fell 6.6% in after-hours trading.

$HLI
Wire

Four Corners Property Trust Q2 AFFO, Revenue Rise

Four Corners Property Trust (FCPT) reported Q2 adjusted funds from operations late Wednesday of $0.45 per diluted share, up from $0.44 a year earlier.Analysts polled by FactSet expected $0.45.Revenue in the quarter ended June 30 rose to $78.4 million from $72.8 million a year earlier.Four analysts expected $79 million.The company's shares rose 2% in after-hours trading.

$FCPT
Wire

Corcept Therapeutics Q2 Earnings, Revenue Rise; Shares Jump After Hours

Corcept Therapeutics (CORT) reported Q2 earnings late Wednesday of $0.36 per diluted share, up from $0.29 a year earlier.Analysts polled by FactSet expected $0.02.Revenue for the three months ended June 30 rose to $256.1 million from $194.4 million a year earlier.Analysts expected $221.1 million.The company boosted full-year revenue guidance to $1.1 billion to $1.2 billion from the prior forecast of $950 million to $1.05 billion.Analysts project $999.5 million.Corcept shares jumped 18% in after-hours trading.

$CORT